New eye drug shows promise in early trial for blinding disease
NCT ID NCT05456828
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-stage study tests an experimental drug called ASKG712, given as an eye injection, for people with wet age-related macular degeneration (a leading cause of vision loss). The main goal is to check safety and how the body handles the drug, with 56 participants receiving different doses. If successful, it could lead to better control of the disease, but ongoing treatment would still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.